allogenic human umbilical cord-derived mesenchymal progenitor cell therapy (Cellular Biomedicine Group)

N/A

Report date: 2025/03/14 16:27:34

Base Information

Drug Nameallogenic human umbilical cord-derived mesenchymal progenitor cell therapy (Cellular Biomedicine Group)
Drug Alias NamehuMPC therapy (Cellualr Biomedicine Group)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapy
Mechanisms of ActionStem cells stimulants
TargetsUpdating
Therapy Area/IndicationsGlaucoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAbelZeta Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbelZeta Inc
Inactive CompaniesN/A
Active IndicationsGlaucoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A